BRPI0517514A - vesìculas bacterianas imunogênicas com proteìnas da membrana externa - Google Patents

vesìculas bacterianas imunogênicas com proteìnas da membrana externa

Info

Publication number
BRPI0517514A
BRPI0517514A BRPI0517514-3A BRPI0517514A BRPI0517514A BR PI0517514 A BRPI0517514 A BR PI0517514A BR PI0517514 A BRPI0517514 A BR PI0517514A BR PI0517514 A BRPI0517514 A BR PI0517514A
Authority
BR
Brazil
Prior art keywords
provides
membrane proteins
bacterium
mlta
outer membrane
Prior art date
Application number
BRPI0517514-3A
Other languages
English (en)
Inventor
Mariagrazia Pizza
Jeannette Adu-Bobie
Nathalie Norais
Germano Ferrari
Guido Grandi
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0517514A publication Critical patent/BRPI0517514A/pt
Publication of BRPI0517514A8 publication Critical patent/BRPI0517514A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

VESìCULAS BACTERIANAS IMUNOGêNICAS COM PROTEìNAS DA MEMBRANA EXTERNA. Knock out do homólogo mltA meningocócico proporciona bactérias que liberam espontaneamente vesículas que São ricas em proteínas da membrana externa imunogênicas e que podem estimular respostas de anticorpo protetoras cruzadas com titulações bactericidas do que OMVs preparadas através de processos normais de produção. Assim, a invenção proporciona uma bactéria tendo uma mutação por knock out de seu gene mltA. A invenção também proporciona uma bactéria em que a bactéria: (i) tem uma parede celular que inclui peptidoglicana; e (ii) não expressa uma proteína tendo a atividade de transglicosilase lítica da proteína MltA. A invenção também proporciona composições compreendendo vesículas que, durante cultura das bactérias da invenção, são liberadas no meio de cultura.
BRPI0517514A 2004-10-29 2005-10-28 Vesículas bacterianas imunogênicas com proteínas da membrana externa BRPI0517514A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0424092.5A GB0424092D0 (en) 2004-10-29 2004-10-29 Immunogenic bacterial vesicles with outer membrane proteins
PCT/IB2005/003494 WO2006046143A2 (en) 2004-10-29 2005-10-28 Immunogenic bacterial vesicles with outer membrane proteins

Publications (2)

Publication Number Publication Date
BRPI0517514A true BRPI0517514A (pt) 2008-10-14
BRPI0517514A8 BRPI0517514A8 (pt) 2017-10-03

Family

ID=33515801

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517514A BRPI0517514A8 (pt) 2004-10-29 2005-10-28 Vesículas bacterianas imunogênicas com proteínas da membrana externa

Country Status (15)

Country Link
US (3) US9206399B2 (pt)
EP (2) EP1804834B1 (pt)
JP (4) JP5362221B2 (pt)
CN (1) CN101048175B (pt)
AT (1) ATE510559T1 (pt)
AU (1) AU2005298332B2 (pt)
BR (1) BRPI0517514A8 (pt)
CA (1) CA2584778C (pt)
CY (1) CY1112105T1 (pt)
ES (1) ES2507499T3 (pt)
GB (1) GB0424092D0 (pt)
NZ (1) NZ553989A (pt)
PL (1) PL2279747T3 (pt)
PT (1) PT2279747E (pt)
WO (1) WO2006046143A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1858919B1 (en) * 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
JP2010500399A (ja) * 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0816284D0 (en) * 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
JP5860402B2 (ja) * 2009-10-08 2016-02-16 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
BR112014019166A2 (pt) 2012-02-02 2017-07-04 Novartis Ag promotores para expressão aumentada de proteína em meningococos
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
EP2953620A1 (en) * 2013-02-07 2015-12-16 GlaxoSmithKline Biologicals SA Pharmaceutical compositions comprising vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
HUE052293T2 (hu) 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa Módosított fHbp meningococcus-polipeptidek
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
CN108220267B (zh) * 2016-12-22 2022-10-04 丰益(上海)生物技术研发中心有限公司 磷脂酶及其应用
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
KR20200136361A (ko) * 2017-12-04 2020-12-07 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 외막 소포의 생성을 위한 개선된 방법
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020146814A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
AU2020225473A1 (en) * 2019-02-22 2021-09-30 Evelo Biosciences, Inc. Bacterial membrane preparations
EP3799884A1 (en) * 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN111440748A (zh) * 2020-05-15 2020-07-24 黑龙江八一农垦大学 一种分离、提纯及鉴定坏死杆菌外膜囊泡的方法
US20240082379A1 (en) * 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH04500203A (ja) 1988-08-25 1992-01-16 ザ　リポソーム　カンパニー，インコーポレイテッド インフルエンザワクチンおよび新規なアジュバント
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE173634T1 (de) 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU707131B2 (en) 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
NZ502437A (en) 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
ES2301181T3 (es) 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002517179A (ja) 1997-11-28 2002-06-18 ジェンセット Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
CN1200730C (zh) 1998-02-12 2005-05-11 惠氏控股有限公司 用白细胞介素－12配制的肺炎球菌和脑膜炎球菌疫苗
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ES2298128T3 (es) 1999-02-22 2008-05-16 Health Protection Agency Composiciones de vacuna neisseriana y metodos.
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
BR0108711A (pt) 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
AU2001280883A1 (en) 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
SI2255826T1 (sl) 2002-08-02 2016-07-29 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CA2550927A1 (en) 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine

Also Published As

Publication number Publication date
WO2006046143A2 (en) 2006-05-04
JP5362221B2 (ja) 2013-12-11
GB0424092D0 (en) 2004-12-01
EP1804834A2 (en) 2007-07-11
ATE510559T1 (de) 2011-06-15
US10336794B2 (en) 2019-07-02
US20180009852A1 (en) 2018-01-11
CY1112105T1 (el) 2015-11-04
PT2279747E (pt) 2014-10-02
US9771399B2 (en) 2017-09-26
JP2016135139A (ja) 2016-07-28
JP2008517617A (ja) 2008-05-29
US9206399B2 (en) 2015-12-08
EP2279747B1 (en) 2014-06-25
ES2507499T3 (es) 2014-10-15
EP1804834B1 (en) 2011-05-25
CN101048175A (zh) 2007-10-03
US20160108094A1 (en) 2016-04-21
CN101048175B (zh) 2013-03-13
BRPI0517514A8 (pt) 2017-10-03
AU2005298332B2 (en) 2012-05-03
PL2279747T3 (pl) 2015-01-30
WO2006046143A3 (en) 2007-03-15
CA2584778A1 (en) 2006-05-04
JP2011188870A (ja) 2011-09-29
CA2584778C (en) 2014-04-08
JP2014039566A (ja) 2014-03-06
NZ553989A (en) 2010-03-26
AU2005298332A1 (en) 2006-05-04
US20100015212A1 (en) 2010-01-21
EP2279747A1 (en) 2011-02-02
JP6077983B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
BRPI0517514A (pt) vesìculas bacterianas imunogênicas com proteìnas da membrana externa
Koch The etiology of tuberculosis
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
BRPI0315228A8 (pt) Vacinas de polipeptídeo para ampla proteção contra linhagens meningocócicas hipervirulentas
CN110072988A (zh) 厌氧性细菌等细菌与上皮细胞的共培养装置及共培养方法
ES2617151T3 (es) Módulo de cultivos celulares
ES2129386T1 (es) Vacuna contra influenza.
BR0114400A (pt) Uso de bactéria de ácido lático probiótica para equilibrar o sistema imunológico da pele
PT717777E (pt) Vacinas de salmonela
NZ590603A (en) Method for preparation of lactic acid bacterium having anti-allergic activity comprising culturing bacterium in casein hydrolysate
FI892065A (fi) Transformerade mjoelksyrebakterier.
BRPI0519923A2 (pt) polipeptìdeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-o-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-o-desacilado, vacina, e , método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo
DE69838173D1 (de) Molkereistarterkultur-abgabesystem und dessen verwendung
AR059863A1 (es) Cepas de lactobacillus helveticus
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
DE60222807D1 (de) Milchproteinbiofilm und verwendungen davon
RS20100249A (en) CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE
BRPI0418310A (pt) linhagem de células-tronco embrionárias, método de preparação da mesma, neuro-progenitor, método de preparação do mesmo e meio de cultura
ATE326978T1 (de) Apoptose-imitierende natürliche vesikel und deren verwendung zur medizinischen behandlung
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
EP1172434A4 (en) VIOLET PHOTOSYNTHETIC BACTERIA AND DIET FOOD
AR042237A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios
BRPI0100837B8 (pt) sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi
Rinaldo Jr et al. Growth of the Pittsburgh pneumonia agent in animal cell cultures
Cole Unifying Microbial Mechanisms: Shared Strategies of Pathogenesis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT)

B25D Requested change of name of applicant approved

Owner name: GSK VACCINES S.R.L (IT)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GSK VACCINES S.R.L (IT)

Free format text: ANULADA A ALTERACAO DE NOME DESPACHO 25.4 PUBLICADA NA RPI NO 2439, DE 03/10/2017, POR TER SIDO INDEVIDA, UMA VEZ QUE NAO FOI DISPONIBILIZADO O RESPECTIVO PARECER.

Owner name: GSK VACCINES S.R.L (IT)

B25D Requested change of name of applicant approved

Owner name: GSK VACCINES S.R.L (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL